Jeff P. Sharman

Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin

Introduction:Patients with relapsed indolent NHL (iNHL) have limited standard treatment options. Lenalidomide combined with rituximab (R ) has shown complimentary clinical activity and is...

Jung R. Ahn ;

Ju Li ;

Mathias D. Rummel ;

Jeff P. Sharman ;

Frederick Lansigan ;

David J. Andorsky ;

Morton Coleman ;

Yacoub Abdulraheem ;

Jason M. Melear ;

Suzanne R. Fanning ;

Kathryn S. Kolibaba ;

Chris Reynolds ;

Grzegorz S. Nowakowski ;

Mecide Gharibo ;

11/04/2022

Conference Coverage

Efficacy of Acalabrutinib With or Without Obinutuzumab Among Patients With Treatment-Naive CLL

12/11/2023

Jeff P. Sharman ;

At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...

At the 65th ASH Annual Meeting,...

12/11/2023

Oncology